Literature DB >> 6198943

A comparison of lymphocyte populations in lung tissue and in bronchoalveolar lavage fluid of rats at various times during the development of bleomycin-induced pulmonary fibrosis.

R S Thrall, R W Barton.   

Abstract

The purpose of this study was to compare lymphocyte populations in lung lavage fluid and in lung tissue during the development of bleomycin-induced pulmonary fibrosis. At various times after bleomycin treatment, animals were killed and lavaged, and lung tissue cells were extracted. Lymphocyte populations were identified by immunofluorescent techniques, using monoclonal antibodies, and quantitated on the fluorescence-activated cell sorter. Normal control rat lung tissue was comprised of 91% T-cells (helper-to-suppressor cell ratio of approximately 1:1) and 9% B-cells. After bleomycin administration, a significant increase in the percentage of B-cells in lung tissue was observed within 3 days, with peak levels (approximately 28%) occurring at 7 days. Changes in the T-cell subset populations were also observed in lung tissue; at 14 days after the administration of bleomycin, the helper-to-suppressor T-cell ratio was 2:1, at 30 and at 120 days, the ratio was reversed to 1:2. These represent significant changes from the 1:1 ratio found in control animals. No lymphocytes were observed in the lavage fluid of control animals or in animals at 30 and 120 days after bleomycin treatment. Significant populations of lymphocytes were found in the lavage fluid at 3, 7, and 14 days after bleomycin treatment. These lymphocytes consisted of approximately 90% T-cells (helper-to-suppressor cell ratio of 1:1) and 10% B-cells. There were no significant changes in the lymphocyte populations found in the lavage fluid after the administration of bleomycin. The results demonstrate that specific lymphocyte populations are changing in lung tissue during the development of the fibrotic process, whereas this shift in populations does not occur in the lymphocyte populations found in lavage fluid.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198943

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  17 in total

1.  FTS reduces bleomycin-induced cytokine and chemokine production and inhibits pulmonary fibrosis in mice.

Authors:  S Yara; K Kawakami; N Kudeken; M Tohyama; K Teruya; T Chinen; A Awaya; A Saito
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Overexpression of the transcription factor GATA-3 enhances the development of pulmonary fibrosis.

Authors:  Toru Kimura; Yukio Ishii; Keigyou Yoh; Yuko Morishima; Takashi Iizuka; Takumi Kiwamoto; Yosuke Matsuno; Shinsuke Homma; Akihiro Nomura; Tohru Sakamoto; Satoru Takahashi; Kiyohisa Sekizawa
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

3.  Quantitative immunohistologic assessment of lymphocyte populations in the pulmonary inflammatory response to intratracheal silica.

Authors:  R K Kumar
Journal:  Am J Pathol       Date:  1989-10       Impact factor: 4.307

4.  Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats.

Authors:  J G Hay; P L Haslam; A Dewar; B Addis; M Turner-Warwick; G J Laurent
Journal:  Thorax       Date:  1987-05       Impact factor: 9.139

5.  Inhibition of bleomycin-induced pulmonary fibrosis by nordihydroguaiaretic acid. The role of alveolar macrophage activation and mediator production.

Authors:  S H Phan; S L Kunkel
Journal:  Am J Pathol       Date:  1986-08       Impact factor: 4.307

6.  Effects of a calmodulin inhibitor on bleomycin-induced lung inflammation in hamsters. Biochemical, morphometric, and bronchoalveolar lavage data.

Authors:  J M Nakashima; D M Hyde; S N Giri
Journal:  Am J Pathol       Date:  1986-09       Impact factor: 4.307

7.  Bronchoalveolar lavage cell populations in bleomycin lung toxicity.

Authors:  D A White; M G Kris; D E Stover
Journal:  Thorax       Date:  1987-07       Impact factor: 9.139

8.  Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity.

Authors:  D A Campbell; L W Poulter; G Janossy; R M du Bois
Journal:  Thorax       Date:  1985-06       Impact factor: 9.139

9.  Time course of bleomycin-induced lung fibrosis.

Authors:  G Izbicki; M J Segel; T G Christensen; M W Conner; R Breuer
Journal:  Int J Exp Pathol       Date:  2002-06       Impact factor: 1.925

10.  Lung lymphocytes in bleomycin-induced pulmonary disease.

Authors:  J P Karpel; T K Aldrich; S Mitsudo; A J Norin
Journal:  Lung       Date:  1989       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.